Achieve Life Sciences (NASDAQ:ACHV) Given a $20.00 Price Target at LADENBURG THALM/SH SH

Achieve Life Sciences (NASDAQ:ACHV) received a $20.00 target price from investment analysts at LADENBURG THALM/SH SH in a research note issued to investors on Tuesday, The Fly reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock.

Shares of NASDAQ:ACHV opened at $2.65 on Tuesday. The company has a market capitalization of $18.20 million, a PE ratio of -0.73 and a beta of 2.66. The company has a quick ratio of 2.63, a current ratio of 2.63 and a debt-to-equity ratio of 0.03. Achieve Life Sciences has a 12 month low of $1.04 and a 12 month high of $7.68.

Achieve Life Sciences (NASDAQ:ACHV) last issued its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.88) EPS for the quarter. As a group, research analysts expect that Achieve Life Sciences will post -1.7 EPS for the current year.

In related news, CEO Richard Alistair Stewart acquired 17,500 shares of the stock in a transaction that occurred on Thursday, May 23rd. The stock was acquired at an average cost of $3.61 per share, for a total transaction of $63,175.00. The transaction was disclosed in a filing with the SEC, which is available through this link. 6.80% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc increased its position in Achieve Life Sciences by 169.3% during the 3rd quarter. Vanguard Group Inc now owns 35,468 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 22,299 shares in the last quarter. Renaissance Technologies LLC increased its position in Achieve Life Sciences by 13.4% during the 1st quarter. Renaissance Technologies LLC now owns 285,661 shares of the biopharmaceutical company’s stock worth $923,000 after purchasing an additional 33,800 shares in the last quarter. Worth Venture Partners LLC increased its position in Achieve Life Sciences by 180.1% during the 4th quarter. Worth Venture Partners LLC now owns 89,632 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 57,632 shares in the last quarter. Finally, Searle & CO. acquired a new position in Achieve Life Sciences during the 1st quarter worth approximately $237,000. Institutional investors and hedge funds own 16.20% of the company’s stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.

Read More: Why is Cost of Capital Important?

The Fly

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.